Infinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in the BIO CEO & Investor Conference from February 16-18. The company will present information regarding eganelisib, an innovative oral immuno-oncology therapeutic targeting immune suppression in cancer. The presentation will be available on demand starting February 16 at 10am EST. Infinity is advancing eganelisib across multiple clinical studies, addressing various cancer types through novel combination therapies. More details can be found at www.infi.com.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will be presenting at the BIO CEO & Investor Conference taking place February 16-18. Presentations details are below:

BIO CEO & Investor Conference Presentation Details:
Date:					February 16 – 18
Presentation:					Available on demand starting February 16th at 10am EST
The link for the presentation will be available at www.infi.com.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. Infinity is advancing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a Phase 2, randomized, placebo-controlled study of eganelisib combined with Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005569/en/

FAQ

When is Infinity Pharmaceuticals presenting at the BIO CEO & Investor Conference?

Infinity Pharmaceuticals will present at the BIO CEO & Investor Conference from February 16-18.

What is eganelisib and its significance?

Eganelisib is a potentially first-in-class oral immuno-oncology therapeutic developed by Infinity Pharmaceuticals that targets immune suppression in cancer.

When will the presentation for Infinity Pharmaceuticals be available?

The presentation will be available on demand starting February 16 at 10am EST.

What clinical studies are related to eganelisib?

Infinity is conducting multiple clinical studies with eganelisib, including MARIO-275 and MARIO-3, targeting various cancer types.

Where can I find more information about Infinity Pharmaceuticals?

More information can be accessed on Infinity Pharmaceuticals' website at www.infi.com.